NASDAQ:ZSQR Coeptis Therapeutics Q4 2025 Earnings Report $10.99 0.00 (0.00%) As of 07/2/2026 04:00 PM Eastern ProfileEarnings HistoryForecast Coeptis Therapeutics EPS ResultsActual EPS-$0.12Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ACoeptis Therapeutics Revenue ResultsActual Revenue$0.86 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACoeptis Therapeutics Announcement DetailsQuarterQ4 2025Date3/19/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Coeptis Therapeutics Earnings HeadlinesCoeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR) Short Interest UpdateJuly 2 at 3:01 AM | americanbankingnews.comZ Squared Inc. Appoints Jeffrey Harris as Chief Technology OfficerJune 30, 2026 | prnewswire.comSell Tesla, Buy the New King of FSD CarsIn 2023, Marc Chaikin's system flagged an automotive stock as bearish - and it fell 35% shortly after. Today, that same stock has earned a 'Very Bullish' rating after forming a major partnership with Nvidia to power AI-driven autonomous vehicles. This barely-known company was selected to handle the complex job of getting Nvidia's self-driving AI safely inside vehicles - positioning it at the center of a massive trend most investors are still missing through Tesla.July 4 at 1:00 AM | Chaikin Analytics (Ad)Z Squared Raises Approximately $15.3 Million in Non-Debt Capital to Advance AI Infrastructure StrategyJune 29, 2026 | prnewswire.comRussell Indexes Add Z Squared Inc. to Russell 2000® and Russell 3000®June 29, 2026 | prnewswire.comZ Squared, Inc. to Acquire Majority Interest in Paradox Data and Its Union County Campus, a Next-Generation Data Center Development Targeting Up to 150 MW of Firm PowerJune 25, 2026 | prnewswire.comSee More Coeptis Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Coeptis Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Coeptis Therapeutics and other key companies, straight to your email. Email Address About Coeptis TherapeuticsCoeptis Therapeutics (NASDAQ:ZSQR), a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.View Coeptis Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 06/29 - 07/03Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive WeaponGeneral Mills Is a 5-Star Turnaround Play for Buy and Hold InvestorsCopper Stocks Are Getting a Bigger Spotlight as Gold’s Rally CracksNike Q4 Beat Masks Core Weakness as Analysts Cut Price TargetsIs the Memory Rally Still Alive After the Semiconductor Sell-Off?Hershey Stock May Be Near a Sweet Spot as Cocoa Pressure Eases Upcoming Earnings PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026)Fastenal (7/14/2026)Cintas (7/15/2026)ASML (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
